Silicon Valley Insider: Cellibre, Applying Cellular Agriculture to Manufacture CBD

The world of sustainable investing is growing, and its important here at Impakter that we keep a pulse on the start-ups and venture capital firms that are making waves in this space. With this in mind, we are excited to announce our new column series, “Silicon Valley Insider”, in which we keep our readers up-to-date on the companies and entrepreneurs that have recently secured financing for their impact-focused ventures. This week, we are highlighting the deal by cellular agriculture company, Cellibre Inc. out of San Diego, CA.

Last week, they closed a financing round of an undisclosed amount. Backers in the deal included Cresco Capital Partners II, LLC, Flatiron Venture Partners, and Delta Emerald Ventures. The company intends to use the funds to accelerate the development of proprietary cells for the production of pure, natural, pharmaceutical-grade cannabinoids via fermentation.

In the Picture: A plant of marijuana. Photo Credit: Unsplash

Cellular agriculture is the production of agricultural products from cell cultures. More simply, cellular agriculture is a method of making foods and products that conventionally come from the harvest of plants and animals, only doing so via fermentation without harvesting plants or animals. The process can be used to make meat, leather, or in Cellibre’s case, cannabinoids. Many of us have heard about cultured meat in recent years, which requires less water and energy to produce and generates 95% lower greenhouse gas emissions than conventionally produced meat.

Cellular agriculture is a dense and complicated topic, so I decided to follow up with the company’s CEO and Founder, Ben Chiarelli, to get his take on the space, learn about his background, and understand his strategy.

Ben’s background is in engineering and finance, but the way he speaks about cellular agriculture you would think he has been in lab coat his entire life. He obtained a Bachelor’s Degree in Mechanical Engineering from Case Western Reserve University in Cleveland, Ohio, and soon after got his MBA from Carnegie Mellon. Professionally, he spent several years on Wall Street as an investment banker for firms like JP Morgan and Jefferies & Company, focusing on Healthcare and related sub-sectors. In 2015, after moving to San Diego to work with one of his clients, he joined forces with Synthetic Genomics, a leading company in the field of synthetic biology founded by Dr. Craig Venter, who helped map the first human genome in the Human Genome Project, and, Dr. Hamilton O. Smith, winner of the Nobel Prize in Medicine in 1978 for his discovery of type II restriction enzymes.

In the Picture: Cellibre’s logo and Cellibre CEO Ben Chiarelli. Photo Credit: Cellibre

Ben spent several years working with the Synthetic Genomics team to find new ways to take the world’s best science and turn it into a business. It was here that he saw the opportunity to apply cellular agriculture to the cannabis plant.

Biology is a manufacturing technology,” Ben began, “all cells have machines and those machines are instructed by DNA to turn nutrients into products. The cannabis plant is a great example. It takes in soil, sunlight and water, and manufactures more than 400 chemicals, more than 100 of which are bioactive.”

He explained that this is why the cannabis plant is a prime target for cellular agriculture. Cannabis products must maintain a level of quality control and consistency, especially with chemicals like THC.

Ben went on to explain that extracting cannabinoids like CBD is arduous, expensive and inconsistent. One kilogram of CBD extract, harvested in the traditional fashion and processed to its pure form, can cost over $5,000 per kilogram.

In the Picture: An indoor garden. Photo Credit: Unsplash

Cellibre now plans to use microorganisms like yeast produce the same, natural CBD with pharmaceutical level precision via fermentation, removing the need for agriculture completely for these extracts.

The environmental implications of manufacturing plant and animal products via fermentation are not lost on Ben, either. He estimates that with a 30,000 square foot facility, they could reasonably extract more CBD than in a five million square foot facility using traditional harvesting and extraction methods. An important factor to keep in mind, considering a 2012 study estimated that indoor cannabis production could account for 1% of the country’s electricity use and is associated with 4600 kilogram of carbon dioxide emissions per kilogram of final product.

Cellibre isn’t the only company to see the “green” in cultured cannabis chemicals. In September of 2016, the Canadian cannabis company Cronos Group (NASDAQ: CRON) joined forces with synthetic biology firm Ginkgo Bioworks in a $122 million deal to develop fermentation processes for manufacturing tetrahydrocannabinol (THC) and cannabidiol (CBD). In March of this year, the California-based synthetic biology company Amryis closed a $300 million deal with biotech startup Lavvan to develop synthetic cannabinoids.

When asked if he sees any other areas of opportunity for cellular agriculture, Ben said, “Biology can touch every industry on the planet.” He referenced the partnership between Twist Bioscience and Microsoft to develop technologies to use DNA to store data.

The Cellibre team plans to focus their efforts exclusively on cannabinoid-based products for the time being.

We look forward to catching up with him later to see his progress.

Other recent deals we are keeping our eye on:

The closing of Generation Investment Management’s recent fund is particularly relevant to the topic of cellular agriculture. Techniques like the ones being used by Cellibre can change the way products are made on an industrial scale.

“We believe that we are at the early stages of a technology-led sustainability revolution, which has the scale of the industrial revolution, and the pace of the digital revolution,” said Al Gore, Chairman and Co-Founder.

Check back next week for more impact-driven deals and news!

In the Cover Picture: Marijuana Leaves Photo Credit: Unsplash

EDITOR’S NOTE: The opinions expressed here by columnists are their own, not those of 

About the Author /

Mike Anderson is a tech enthusiast and entrepreneur living in San Francisco. He’s a Growth Manager with an AI-powered virtual care company, Intellivisit, and is the co-founder of a SaaS fundraising platform for schools and nonprofits, HowToFund. Mike spent the last 7 years working for an investment bank and an investor relations consulting firm where he collaborated with public companies to craft their financial message. He holds an MBA from Loyola University Chicago, and a Bachelor’s degree in Finance from Augustana College.

Post a Comment

Scroll Up